Journal of Enzyme Inhibition and Medicinal Chemistry (Dec 2023)

Design, synthesis and antitumor evaluation of novel pyrazolo[3,4-d]pyrimidines incorporating different amino acid conjugates as potential DHFR inhibitors

  • Ibrahim M. Salem,
  • Samia M. Mostafa,
  • Ismail Salama,
  • Osama I. El-Sabbagh,
  • Wael A. H. Hegazy,
  • Tarek S. Ibrahim

DOI
https://doi.org/10.1080/14756366.2022.2142786
Journal volume & issue
Vol. 38, no. 1
pp. 203 – 215

Abstract

Read online

The present study aimed to investigate the antitumor effect of simultaneous inhibition of dihydrofolate reductase (DHFR) enzyme. We designed some novel pyrazolo[3,4-d]pyrimidines bearing different amino acid conjugates as efficient antifolate agents attributable to their structural similarity with methotrexate (MTX) and MTX-related antifolates. All compounds were tested to screen their enzymatic inhibition against DHFR compared with the reference drug MTX and for their in vitro antitumor cytotoxicity against six MTX-resistant cancer cell lines. The flow cytometry indicated that the most potent compound 7f arrested MCF-7 cells in the S-phase and induced apoptosis. Western blot for visualisation proved the ability of compound 7f to induce the expression of proapoptotic caspases and Bax proteins in MCF-7 breast cancer cell line beside its ability to diminish the expression of antiapoptotic Bcl-2 protein. Molecular modelling studies concluded that compound 7f displayed better binding energy than that of the normal ligand MTX.

Keywords